AI Article Synopsis
- The objective of the study was to assess the safety and effectiveness of daprodustat, a treatment for anemia in patients with chronic kidney disease (CKD).
- Literature was analyzed to determine the drug's effects on hemoglobin levels and the occurrence of major adverse cardiovascular events compared to traditional treatments.
- Daprodustat was found to be effective in raising hemoglobin levels in CKD patients on dialysis without increasing cardiovascular risks, and it's been approved for use by the FDA in those patients since 2023.
Article Abstract
Objective: The objective was to review the safety and efficacy of daprodustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) in the treatment of anemia of chronic kidney disease (CKD).
Data Sources: A literature search was conducted in MEDLINE, EMBASE, and ClinicalTrials.gov using the keywords "daprodustat," "GSK1278863," and "hypoxia-inducible factor-prolyl hydroxylase inhibitors" from January 2010 through November 2023.
Study Selection And Data Extraction: Literature was included if it evaluated pharmacology, pharmacokinetics, efficacy, and/or safety of daprodustat in human subjects and was reported in English. The manufacturer's product monograph was also utilized.
Data Synthesis: Daprodustat significantly increased hemoglobin levels in CKD patients on dialysis (difference 0.18 g/dL) and not on dialysis (difference 0.08 g/dL) over 52-week treatment periods compared with erythropoiesis stimulating agents (ESA) in Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat (ASCEND)-D and ASCEND-ND, respectively. First occurrence of major adverse cardiovascular events (MACEs) was similar between daprodustat and ESAs in both trials.
Relevance To Patient Care And Clinical Practice In Comparison To Existing Drugs: Daprodustat can be used in patients with CKD on dialysis and already receiving an ESA for at least 6 weeks to further increase serum hemoglobin levels without increasing the risk of MACE. Adverse effects of daprodustat that may occur more than ESAs include headache, emesis, and thrombosis.
Conclusions: Daprodustat is a novel oral, non-iron therapy for treatment of anemia of CKD. It was Food and Drug Administration approved in 2023 in patients already receiving dialysis for at least 4 months but not in non-dialysis patients. Long-term data for safety and additional benefits are pending.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10600280241241563 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Managing Zinc Supplementation in Hemodialysis Patients: Balancing and Preventing Deficiencies in Serum Copper and Zinc Levels with and Without HIF-PH Inhibitors.
Nutrients
November 2024
Dialysis Center, Tesseikai Neurosurgical Hospital, 28-1 Nakanohonmachi, Shijonawate 575-8511, Japan.
Background/objectives: Zinc supplementation induces metallothionein, leading to reduced serum copper levels. Conversely, serum copper concentrations tend to rise with the use of HIF-PH inhibitors.
Methods: To establish a safe level of zinc supplementation that avoids copper deficiency, serum copper and zinc concentrations measured every three months were retrospectively analyzed over five years in 50 patients undergoing hemodialysis.
Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor.
Nat Biotechnol
December 2024
Insilico Medicine US, Inc., Boston, MA, USA.
Hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors have been approved for treating renal anemia yet have failed clinical testing for inflammatory bowel disease because of a lack of efficacy. Here we used a multimodel multimodal generative artificial intelligence platform to design an orally gut-restricted selective PHD1 and PHD2 inhibitor that exhibits favorable safety and pharmacokinetic profiles in preclinical studies. ISM012-042 restores intestinal barrier function and alleviates gut inflammation in multiple experimental colitis models.
View Article and Find Full Text PDFBackground Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor used in renal anemia treatment, has been associated with thyroid hormone suppression. This study investigated the patterns of thyroid profile changes following roxadustat administration and their clinical implications. Methods In this retrospective study (2019-2023) at Shenzhen Second People's Hospital, patients were categorized based on TSH reduction during follow-up (≥50% decrease vs<50% decrease).
View Article and Find Full Text PDFAnemia, iron metabolism, and anemia medication habits in patients undergoing maintenance hemodialysis and peritoneal dialysis are different: a multicenter investigation.
Clin Exp Nephrol
December 2024
Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Yishan Road, Shanghai, China.
Background: This study aimed to investigate anemia, iron metabolism status, and treatment in patients undergoing maintenance hemodialysis (HD) and peritoneal dialysis (PD).
Methods: Patients aged ≥ 18 years undergoing HD and PD were surveyed using a case report form to collect information.
Results: Data were collected from 1071 patients undergoing HD and 630 undergoing PD at eight centers.
[Update on Research and Treatment of Chronic Kidney Disease].
No Shinkei Geka
November 2024
Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine.
The kidney and brain share strain vessels, which are short and small arterioles that branch out of larger arteries. These vessels are vulnerable to risk factors such as atherosclerosis, old age, hypertension, diabetes, dyslipidemia, and smoking. The nervous system and the kidneys interact to maintain homeostasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!